Journal: Journal of neuropathology and experimental neurology

Article Title: Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights.

doi: 10.1093/jnen/64.4.280

Figure Lengend Snippet: FIGURE 9. Hyaline deposits. Pallidum. (A) Pleomorphic hyaline deposits, some containing nuclei, within the same area of GPe as in Figure 6A. (B) Prussian-blue reactivity. (C) PTAH reactivity. (D) Polyclonal anti-ferritin immunoreactivity. (E) Rare association of hyaline deposits with GFAP-immunoreactive astrocyte. (F) HO-2-immunoreactivity. Original magnifications: (A) Hematoxylin and eosin, 1503; (B) Perl’s stain, 2203; (C) 2203; (D) 2503; (E) 2203; (F) 2503.

Article Snippet: In order to identify the cell(s) of origin of the unique vacuolated nuclei, antibodies to S-100 (polyclonal, 1:20k, Lot #941; Innovation Foundation, Toronto, Ontario, Canada), GFAP, CD68 (monoclonal, 1:200, Lot #120201; DAKO), and carbonic anhydrase II (CAII) (polyclonal, 100-401-136/4383, 1:15k with retrieval; Rockland, Gilbertsville, PA) were applied to sections of basal ganglia and cerebellum, while antibodies to synaptophysin (monoclonal, 1:100 with retrieval, #M0363-UC/0403; Biogenex, San Ramon, CA), PGP 9.5 (polyclonal, 1:1,000 with retrieval, Lot #11830; Biogenesis, Handsown, NH), neurofilament protein 2F11 (monoclonal, 1:350, #M0762/117 DAKO) (101), and amyloid precursor protein (APP A4; monoclonal, 1:20K with heat retrieval, #23080547, Chemicon) were applied to the section of basal ganglia.

Techniques: Staining

Journal: Frontiers in Aging Neuroscience

Article Title: The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome

doi: 10.3389/fnagi.2021.754123

Figure Lengend Snippet: List of antibodies used for Immunofluorescence Staining (IF) or immunocytochemistry (ICC).

Article Snippet: GFAP , Rabbit , , 1:500 , Neuromics , RA22101 , IF.

Techniques: Immunofluorescence, Staining, Immunocytochemistry

Journal: International journal of immunopathology and pharmacology

Article Title: Administration of anti-GFAP antibodies increases CGRP expression and increases pain hypersensitivity in spinal cord injured animals.

doi: 10.1177/03946320251320754

Figure Lengend Snippet: Figure 2. Plasma levels of immunoreactivity to GFAP were significantly higher in the anti-GFAP treated group at day 14 and day 28 compared to IgG-treated and sham saline-treated rats. Those receiving the anti-GFAP showed a mean difference on day 14: 2.97, t = 4.58, p < 0.001; and mean difference on day 28: 1.81, t = 2.8, p = 0.007 compared to SCI rats receiving normal rat IgG(*). A standard curve was generated by serial dilution of purified recombinant GFAP protein for between- assay comparison, measurements are expressed as ng/ul of GFAP. GFAP: glial fibrillary acidic protein; IgG: immunoglobulin G.

Article Snippet: The specificity and sensitivity of antibodies was verified using immunohistochemistry compared to commercial controls, and using Western blot against both purified recombinant GFAP protein (OriGene, Rockville, MD) and brain tissue.

Techniques: Clinical Proteomics, Saline, Generated, Serial Dilution, Purification, Recombinant, Comparison

Journal: International journal of immunopathology and pharmacology

Article Title: Administration of anti-GFAP antibodies increases CGRP expression and increases pain hypersensitivity in spinal cord injured animals.

doi: 10.1177/03946320251320754

Figure Lengend Snippet: Figure 3. There was a significant difference in mean CGRP expression among the treatment groups (F(2,12) = 6.519, p = 0.012)(*). Anti-GFAP treated mean CGRP expression (M = 20.09, SD = 2.42) was significantly increased compared to both laminectomy-only (M = 13.71, SD = 2.555), p = 0.007(*), and IgG treated groups (M = 15.62, SD = 3.19), p = 0.017(*). No significant difference in CGRP expression was determined between the IgG-treated rats and laminectomy-only rats (p = 0.351). These results indicate that the anti-GFAP treatment increased expression of CGRP. CGRP: calcitonin gene-related peptide.

Article Snippet: The specificity and sensitivity of antibodies was verified using immunohistochemistry compared to commercial controls, and using Western blot against both purified recombinant GFAP protein (OriGene, Rockville, MD) and brain tissue.

Techniques: Expressing

Journal: International journal of immunopathology and pharmacology

Article Title: Administration of anti-GFAP antibodies increases CGRP expression and increases pain hypersensitivity in spinal cord injured animals.

doi: 10.1177/03946320251320754

Figure Lengend Snippet: Figure 4. (a) Von Frey assay testing indicated a lower paw withdrawal threshold in the injured groups compared to laminectomy control rats at 1- and 2-month time points. (b) MCAP revealed significantly reduced number of crosses in the anti-GFAP treated rats compared to laminectomy controls at 2 months post-injury (*) indicating avoidance of the crossing, suggesting hyperalgesia. This was not observed in the IgG- or saline-treated animals. GFAP: glial fibrillary acidic protein; IgG: immunoglobulin G; MCAP: mechanical conflict-avoidance paradigm.

Article Snippet: The specificity and sensitivity of antibodies was verified using immunohistochemistry compared to commercial controls, and using Western blot against both purified recombinant GFAP protein (OriGene, Rockville, MD) and brain tissue.

Techniques: Control, Saline

Journal: Cell reports

Article Title: Astrocytes Amplify Neuronal Dendritic Volume Transmission Stimulated by Norepinephrine

doi: 10.1016/j.celrep.2019.11.092

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: rabbit anti GFAP , Phosphosolution , Cat# 620-GFAP; RRID:AB_2492124.

Techniques: Virus, Plasmid Preparation, Recombinant, Software